[go: up one dir, main page]

PE20040086A1 - Polimorfo del acido 4-[2- [4-[1-(2-etoxietil)-1h-bencimidazol-2-il]-1-piperidinil]etil] -o,o-dimetil-bencenoacetico - Google Patents

Polimorfo del acido 4-[2- [4-[1-(2-etoxietil)-1h-bencimidazol-2-il]-1-piperidinil]etil] -o,o-dimetil-bencenoacetico

Info

Publication number
PE20040086A1
PE20040086A1 PE2003000376A PE2003000376A PE20040086A1 PE 20040086 A1 PE20040086 A1 PE 20040086A1 PE 2003000376 A PE2003000376 A PE 2003000376A PE 2003000376 A PE2003000376 A PE 2003000376A PE 20040086 A1 PE20040086 A1 PE 20040086A1
Authority
PE
Peru
Prior art keywords
piperidinyl
dimethyl
ethyl
refers
benzenoacetico
Prior art date
Application number
PE2003000376A
Other languages
English (en)
Inventor
Venero Aurelio Orjales
Martin Maravillas Bordell
Mori Gonzalo Canal
Fuente Haydee Blanco
De Pablo Maria Luisa Lucero
Royo Victor Rubio
Pestana Ramon Mosquera
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040086(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of PE20040086A1 publication Critical patent/PE20040086A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN POLIMORFO DEL ACIDO 4- [2- [4- [1-(2-ETOXIETIL)-1H-BENCIMIDAZO -2-IL]-1-PIPERIDINIL] ETIL] -O,O-DIMETIL-BENCENOACETICO (BILASTINA) CARACTERIZADO POR SU ANALISIS CRISTALOGRAFICO DE RAYOS-X, CON PARAMETROS DE CRISTAL Y QUE POSEE UN ESPECTRO INFRARROJO EN BROMURO POTASICO CON LAS SIGUIENTES BANDAS(cm-1): 3057, 2929, 2883, 2857, 2797, 1666, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA PREPARAR EL POLIMORFO 1 DE LA BILASTINA QUE CONSISTE EN CALENTAR LA BILASTINA EN UN DISOLVENTE SELECCIONADO ENTRE ALCOHOLES DE CADENA CORTA PREFERENTEMENTE ALCOHOL ISOPROPILICO Y n-BUTANOL, ACETONA Y SUS MEZCLAS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA UTIL PARA EL TRATAMIENTO DE ALERGIAS
PE2003000376A 2002-04-19 2003-04-14 Polimorfo del acido 4-[2- [4-[1-(2-etoxietil)-1h-bencimidazol-2-il]-1-piperidinil]etil] -o,o-dimetil-bencenoacetico PE20040086A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (1)

Publication Number Publication Date
PE20040086A1 true PE20040086A1 (es) 2004-04-27

Family

ID=29225789

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000376A PE20040086A1 (es) 2002-04-19 2003-04-14 Polimorfo del acido 4-[2- [4-[1-(2-etoxietil)-1h-bencimidazol-2-il]-1-piperidinil]etil] -o,o-dimetil-bencenoacetico

Country Status (30)

Country Link
US (2) US7612095B2 (es)
EP (1) EP1505066B1 (es)
JP (1) JP5142448B2 (es)
KR (1) KR100673140B1 (es)
CN (1) CN1290843C (es)
AR (1) AR039423A1 (es)
AT (1) ATE347550T1 (es)
AU (1) AU2002255017B2 (es)
BG (1) BG66302B1 (es)
BR (1) BRPI0215703B8 (es)
CA (1) CA2484460C (es)
CY (2) CY1107564T1 (es)
CZ (1) CZ305162B6 (es)
DE (1) DE60216641T2 (es)
DK (1) DK1505066T3 (es)
ES (1) ES2278018T3 (es)
HR (1) HRP20041048B1 (es)
HU (1) HU230032B1 (es)
IL (1) IL164645A (es)
MX (1) MXPA04010313A (es)
NO (1) NO329327B1 (es)
NZ (1) NZ536551A (es)
PA (1) PA8571201A1 (es)
PE (1) PE20040086A1 (es)
PT (1) PT1505066E (es)
SI (1) SI1505066T1 (es)
SK (1) SK288052B6 (es)
UA (1) UA76866C2 (es)
UY (1) UY27762A1 (es)
WO (1) WO2003089425A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa 4−[2−[1−(2−エトキシエチル)−1H−ベンズイミダゾール−2−イル]−1−ピペリジニル]エチル]−α,α−ジメチルベンゼノ酢酸の多形体
US20140194111A1 (en) * 2011-06-30 2014-07-10 Panasonic Corporation Communication system, user terminal, and communication device
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
LT3327012T (lt) 2015-07-24 2021-09-10 Urquima, S.A. Bilastino kristalinės formos ir jų gamybos būdai
EP3170816A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
EP3170817A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
EP3452462A4 (en) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof
ES2813561T3 (es) 2017-09-07 2021-03-24 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica en comprimido que comprende bilastina
EP3470062B1 (en) 2017-12-18 2020-10-28 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate
WO2019097091A1 (en) 2017-12-18 2019-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler
US20210128544A1 (en) 2018-01-18 2021-05-06 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
EP4267109A1 (en) 2020-12-23 2023-11-01 Noucor Health S.A. A non-micronized bilastine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
MXPA01010472A (es) * 1999-04-16 2002-05-06 Reddy Research Foundation Formas polimorficas novedosas de un agente contra la diabetes; procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
NZ515168A (en) * 1999-04-23 2004-02-27 Smithkline Beecham Plc Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt

Also Published As

Publication number Publication date
CY2013015I2 (el) 2015-08-05
EP1505066B1 (en) 2006-12-06
CY2013015I1 (el) 2015-08-05
PA8571201A1 (es) 2003-12-10
IL164645A0 (en) 2005-12-18
ES2278018T3 (es) 2007-08-01
WO2003089425A1 (es) 2003-10-30
BRPI0215703B1 (pt) 2017-06-27
JP5142448B2 (ja) 2013-02-13
US20100004285A1 (en) 2010-01-07
DK1505066T3 (da) 2007-03-19
CZ305162B6 (cs) 2015-05-27
CN1628112A (zh) 2005-06-15
NO20044999L (no) 2005-01-14
NZ536551A (en) 2006-08-31
EP1505066A1 (en) 2005-02-09
SI1505066T1 (sl) 2007-04-30
AU2002255017A1 (en) 2003-11-03
DE60216641D1 (de) 2007-01-18
CY1107564T1 (el) 2013-03-13
DE60216641T2 (de) 2007-09-27
KR20050005448A (ko) 2005-01-13
CZ20041122A3 (cs) 2005-03-16
IL164645A (en) 2010-11-30
MXPA04010313A (es) 2005-06-08
HRP20041048A9 (hr) 2013-01-31
HRP20041048B1 (hr) 2013-04-30
SK50202004A3 (sk) 2005-05-05
HUP0500241A2 (hu) 2005-06-28
CA2484460C (en) 2009-09-29
US20050203141A1 (en) 2005-09-15
HU230032B1 (hu) 2015-05-28
HK1072772A1 (en) 2005-09-09
ATE347550T1 (de) 2006-12-15
NO329327B1 (no) 2010-09-27
PT1505066E (pt) 2007-03-30
BG66302B1 (bg) 2013-03-29
CN1290843C (zh) 2006-12-20
BR0215703A (pt) 2005-02-01
AU2002255017B2 (en) 2008-11-13
CA2484460A1 (en) 2003-10-30
UY27762A1 (es) 2003-09-30
KR100673140B1 (ko) 2007-01-22
AR039423A1 (es) 2005-02-16
JP2005529120A (ja) 2005-09-29
BG108941A (en) 2005-12-30
SK288052B6 (sk) 2013-03-01
HRP20041048A2 (en) 2005-02-28
US7612095B2 (en) 2009-11-03
BRPI0215703B8 (pt) 2021-05-25
UA76866C2 (uk) 2006-09-15

Similar Documents

Publication Publication Date Title
PE20040086A1 (es) Polimorfo del acido 4-[2- [4-[1-(2-etoxietil)-1h-bencimidazol-2-il]-1-piperidinil]etil] -o,o-dimetil-bencenoacetico
NO20081212L (no) Xantinderivater som selektive HM74A agonister
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AR056055A1 (es) Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno
EA200501222A1 (ru) Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
PE20040897A1 (es) 8-[3-amino-piperidin-1-il]-xantinas y su preparacion como medicamentos
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
ECSP055681A (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
DOP2003000566A (es) Cicloalcanindoles con sustitución con fluor, composiciones que contienen estos compuestos y metodos de preparación para un medicamento
UY27882A1 (es) Compuestos quimicos
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
PE20060210A1 (es) 8-[3-amino-piperidin-1-il]-xantinas como inhibidores de dpp-iv
CO5650227A2 (es) Derivados del acido propionico utiles en desordenes lipidicos
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
EA200701164A1 (ru) Способ получения аннелированных производных пиперазин-2-она и соответствующие промежуточные продукты
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
SE0300850D0 (sv) Chemical compounds
UY28731A1 (es) Compuestos quimicos
DE60321452D1 (de) Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate
ES2155621T3 (es) Derivados azo del acido 5-aminosalicilico para el tratamiento de la enfermedad inflamatoria intestinal.
Nakao et al. Penasulfate A, a new α-glucosidase inhibitor from a marine sponge Penares sp.
UY29445A1 (es) Composiciones para la transmisión transmucosa oral de la metformina

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration